Apolipoprotein(a) messenger RNA (LPA mRNA) (LPA mRNA)

LPA mRNA is the messenger RNA transcript of the LPA gene, which encodes apolipoprotein(a), a key structural component of lipoprotein(a) [Lp(a)] [1]. Lp(a) is a low-density lipoprotein-like particle that is independently associated with an increased risk of atherosclerotic cardiovascular disease and calcific aortic valve stenosis [1, 3]. Because Lp(a) levels are primarily determined by genetics and are resistant to traditional lipid-lowering therapies, LPA mRNA has emerged as a high-priority therapeutic target [2]. Current pharmacological approaches include antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) designed to bind specifically to the LPA mRNA in the liver [3, 4]. These agents facilitate the degradation of the mRNA transcript, thereby inhibiting the synthesis of apolipoprotein(a) and significantly lowering circulating Lp(a) concentrations [2, 3]. Clinical trials for drugs like pelacarsen and olpasiran have demonstrated the efficacy of this approach in achieving substantial reductions in Lp(a), offering a potential new pathway for reducing cardiovascular events in high-risk patients [2, 3]. The specificity of these RNA-based therapies allows for potent inhibition of the target with a relatively long duration of action, often requiring only monthly or quarterly administration [2]. Monitoring of plasma Lp(a) levels serves as a primary biomarker for assessing the pharmacodynamic effect of these mRNA-targeting agents [1].

Other names

Apo(a) mRNALipoprotein(a) mRNALPA transcriptApolipoprotein(a) transcript

Antisense oligonucleotides (ASOs) bind to the LPA mRNA and recruit RNase H1 to degrade the transcript, while small interfering RNAs (siRNAs) utilize the RNA-induced silencing complex (RISC) to cleave the mRNA, both resulting in reduced translation of apolipoprotein(a) [2, 3].